Researchers analyzed the associations between eosinophil, lymphocyte counts and various forms Healio, 1 month ago
New Phase 2 Data Show Nearly Half of Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond to Treatment with Ibrutinib (IMBRUVICA®) - Nasdaq, 3 days ago
RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months - American Journal of Managed Care, 4 days ago
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.
Background: A systemic immune-inflammation index (SII) based on neutrophil (N), lymphocyte (L), and platelet (P) counts has shown a prognostic impact in several solid tumors. The aim of this study is to evaluate the prognostic role of SII in ...UroToday, 1 month ago
European Commission Grants Conditional Marketing Approval for AbbVie's VENCLYXTO (venetoclax) Monotherapy for..
- VENCLYXTO (venetoclax) monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor ...ADVFN India, 1 day ago Orphan designation: Venetoclax, for the: Treatment of multiple myeloma European Medicines Agency, 3 weeks ago
Patients with follicular lymphoma may soon have a new treatment option, as Genentech recently demonstrated that Gazyva (obinutuzumab) improved survival times without disease progression compared to standard treatment with Rituxan (rituximab). Data ...LymphomaNewsToday.com, 7 minutes ago Genentech's Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to Rituxan Benzinga.com, 4 days ago Genentechs Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer Newswire Today, 3 days ago Genentech???s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared To Rituxan BioSpace, 3 days ago
Advanced search A 73-year-old retired analytic chemist presented with 4 weeks of epigastric discomfort, weight loss and loose stools. His medical history revealed pancreatic insufficiency on the background of a pancreatic mass, which had resolved ...British Journal of the Gut, 2 days ago
Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting
SAN DIEGO--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today highlighted long-term follow-up data evaluating ADCETRIS (brentuximab vedotin) in T-cell lymphoma at the 58 th American Society of Hematology ...Business Wire, 4 days ago SEATTLE GENETICS : Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting 4 Traders, 4 days ago Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting Yahoo! Singapore, 3 days ago Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma Nasdaq, 1 month ago
Data at ASH 2016 Show Strong, Lasting Efficacy of IMBRUVICA® (ibrutinib) Through Five Years of Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
SAN DIEGO AND RARITAN, N.J., Dec. 3, 2016 /PRNewswire/ -- Today, Janssen Research & Development, LLC (Janssen) announced the longest follow-up results to date of patients treated with IMBRUVICA® (ibrutinib) for chronic lymphocytic leukemia/small ...Yahoo! Finance, 5 days ago Janssen R&D Release: Data At American Society of Hematology 2016 Show Strong, Lasting Efficacy Of IMBRUVICA (Ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) BioSpace, 4 days ago
More from: , TickerTech.com...and 4 other sources
A man in his 70s with a history of chronic lymphocytic leukemia (CLL) and prescribed cyclosporine, 100 mg twice daily, for pure red cell aplasia was admitted for spreading painful blisters on the hands and feet. He had initially developed ...Journal of the American Medical Association, 1 month ago
New Ibrutinib (IMBRUVICA®) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma (MZL), a Rare, Incurable Type of Non-Hodgkin's Lymphoma
SAN DIEGO and RARITAN, N.J., Dec. 5, 2016 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced results from a Phase 2 study demonstrating a 48% overall response rate (ORR) as assessed by an Independent Review Committee (IRC) ...TickerTech.com, 3 days ago Janssen R&D Release: New Ibrutinib (IMBRUVICA) Phase 2 Data Demonstrate Promise In Relapsed/Refractory Marginal Zone Lymphoma (MZL), A Rare, Incurable Type Of Non-Hodgkin's Lymphoma BioSpace, 3 days ago
More from: , PR Newswire...and 4 other sources
Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting
- Data Demonstrate Robust Response Rates Enabling Transplantation or Donor Lymphocyte Infusions in Patients with Heavily Pretreated Acute Myeloid Leukemia - NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) Karyopharm Therapeutics Inc.Pharmacy Choice, 4 days ago Karyopharm Presents Updated Phase II SAIL Relapsed/Refractory AML Clinical Data At The American Society of Hematology 2016 Annual Meeting BioSpace, 4 days ago
on your WebpageAdd Widget >Get your members hooked!